ANI Pharmaceuticals Acquires Commercial And Pipeline Generic Products From Amerigen Pharmaceuticals, Ltd. For $52.5M In Cash At Close And Up To $25M In Contingent Profit Share Payments Over The Next Four Years

ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ:ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up

Benzinga · 01/09/2020 13:35

ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ:ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up to $25M in contingent profit share payments over the next four years. The contingent payments are earned when annual gross profit exceeds a minimum threshold and are earned on a subset of the acquired products. The acquired portfolio includes ten commercial products, three approved products with launches pending, four filed products and four in-development products as well as a license to commercialize two approved products. The transaction was funded from cash on hand.